{"pmid":32304634,"title":"The UK Coronavirus Cancer Monitoring Project: protecting patients with cancer in the era of COVID-19.","text":["The UK Coronavirus Cancer Monitoring Project: protecting patients with cancer in the era of COVID-19.","Lancet Oncol","32304634"],"journal":"Lancet Oncol","date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304634","week":"202016|Apr 13 - Apr 19","doi":"10.1016/S1470-2045(20)30230-8","source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"_version_":1664431720431091712,"score":8.233237,"similar":[{"pmid":32302754,"title":"Managing patients with cancer in the COVID-19 era.","text":["Managing patients with cancer in the COVID-19 era.","Eur J Cancer","Peng, Ling","Zagorac, Sladjana","Stebbing, Justin","32302754"],"journal":"Eur J Cancer","authors":["Peng, Ling","Zagorac, Sladjana","Stebbing, Justin"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302754","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.ejca.2020.03.028","source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"_version_":1664357978658045954,"score":75.89933},{"pmid":32114746,"title":"[Drug interaction monitoring of lopinavir / ritonavir in COVID-19 patients with cancer].","text":["[Drug interaction monitoring of lopinavir / ritonavir in COVID-19 patients with cancer].","Zhonghua Nei Ke Za Zhi","Zheng, X W","Tao, G","Zhang, Y W","Yang, G N","Huang, P","32114746"],"journal":"Zhonghua Nei Ke Za Zhi","authors":["Zheng, X W","Tao, G","Zhang, Y W","Yang, G N","Huang, P"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32114746","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112138-20200219-00097","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Ritonavir","Lopinavir"],"_version_":1663352134348832768,"score":69.417206},{"pmid":32220659,"pmcid":"PMC7118635","title":"The official French guidelines to protect patients with cancer against SARS-CoV-2 infection.","text":["The official French guidelines to protect patients with cancer against SARS-CoV-2 infection.","Lancet Oncol","You, Benoit","Ravaud, Alain","Canivet, Anne","Ganem, Gerard","Giraud, Philippe","Guimbaud, Rosine","Kaluzinski, Laure","Krakowski, Ivan","Mayeur, Didier","Grellety, Thomas","Lotz, Jean-Pierre","32220659"],"journal":"Lancet Oncol","authors":["You, Benoit","Ravaud, Alain","Canivet, Anne","Ganem, Gerard","Giraud, Philippe","Guimbaud, Rosine","Kaluzinski, Laure","Krakowski, Ivan","Mayeur, Didier","Grellety, Thomas","Lotz, Jean-Pierre"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32220659","week":"202014|Mar 30 - Apr 05","doi":"10.1016/S1470-2045(20)30204-7","source":"PubMed","locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1663352135179304962,"score":57.95225},{"pmid":32294611,"title":"A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19-positive patients with cancer.","text":["A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19-positive patients with cancer.","Eur J Cancer","Scotte, Florian","Minvielle, Etienne","Mir, Olivier","Andre, Fabrice","Barlesi, Fabrice","Soria, Jean-Charles","32294611"],"journal":"Eur J Cancer","authors":["Scotte, Florian","Minvielle, Etienne","Mir, Olivier","Andre, Fabrice","Barlesi, Fabrice","Soria, Jean-Charles"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294611","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.ejca.2020.03.020","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664266295837720577,"score":54.029278},{"pmid":32304435,"title":"The Impact of the COVID-19 Pandemic on Cancer Patients.","text":["The Impact of the COVID-19 Pandemic on Cancer Patients.","In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19). Severe complications have been reported to occur in 33% of patients with COVID-19 and include acute respiratory distress syndrome, acute renal failure, acute respiratory injury, septic shock, and severe pneumonia. Currently, there is no specific treatment or approved vaccine against COVID-19 and many clinical trials are currently investigating potential medications to treat COVID-19. The immunosuppressed status of some cancer patients (whether caused by the disease itself or the treatment) increases their risk of infection compared with the general population. This short review aims to focus on the impact of COVID-19 on a cancer patient and discuss management options and recommendation in addition to highlighting the currently available clinical guidelines and resources.","Am J Clin Oncol","Al-Quteimat, Osama M","Amer, Amer Mustafa","32304435"],"abstract":["In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19). Severe complications have been reported to occur in 33% of patients with COVID-19 and include acute respiratory distress syndrome, acute renal failure, acute respiratory injury, septic shock, and severe pneumonia. Currently, there is no specific treatment or approved vaccine against COVID-19 and many clinical trials are currently investigating potential medications to treat COVID-19. The immunosuppressed status of some cancer patients (whether caused by the disease itself or the treatment) increases their risk of infection compared with the general population. This short review aims to focus on the impact of COVID-19 on a cancer patient and discuss management options and recommendation in addition to highlighting the currently available clinical guidelines and resources."],"journal":"Am J Clin Oncol","authors":["Al-Quteimat, Osama M","Amer, Amer Mustafa"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304435","week":"202016|Apr 13 - Apr 19","doi":"10.1097/COC.0000000000000712","source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"_version_":1664431720391245824,"score":52.464813}]}